Study #2023-0631
A randomized, double-blind, international multicenter, phase III study to evaluate the antitumor efficacy and safety of HLX10 (recombinant humanized anti-PD-1 monoclonal antibody injection) or Placebo in combination with chemotherapy (carboplatin/cisplatin-etoposide) and concurrent radiotherapy in patients with limited-stage small cell lung cancer (LS-SCLC)
MD Anderson Study Status
Not Accepting
Treatment Agent
HLX10, carboplatin/cisplatin-etoposide, Placebo
Description
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Limited-Stage Small Cell Lung Cancer
Study phase:
Phase III
Physician name:
Jianjun Zhang
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-660-1449
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.